Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05504837 · ClinicalTrials.gov registry record · Phase 1
A Study Assessing KB407 for the Treatment of Cystic Fibrosis
A Phase 1 study of Cystic Fibrosis, sponsored by Krystal Biotech.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 5
- Study locations
NCT05504837 is a Phase 1 study of Cystic Fibrosis that is actively recruiting participants, run by Krystal Biotech. The registered enrollment target is 12 participants, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The trial reports 5 study locations across 4 states.
The verdict
NCT05504837, a Phase 1 study of Cystic Fibrosis, is actively recruiting participants, sponsored by Krystal Biotech.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 5
- Study locations
Study Summary
This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
Conditions Studied
Interventions
- BIOLOGICAL KB407 (Nebulization)
Study Locations (5)
New York
- New York Medical College/ Boston Children's Health Physicians - Hawthorne
- Northwell Health Physicians - New York
Florida
- University of Florida, Gainesville - Gainesville
Illinois
- The Cystic Fibrosis Institute - Northfield
North Carolina
- Atrium Health Wake Forest Baptist Medical Center - Winston-Salem
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2023-06-30 |
| Est. Completion | 2026-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05504837
The ClinicalTrials.gov registry entry for NCT05504837 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 179-participant average among 169 other Cystic Fibrosis trials with a reported enrollment target (93% lower). The listed sponsor is Krystal Biotech, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cystic Fibrosis appearing as the primary indexed condition, and to 1 intervention - of which KB407 (Nebulization) is the first listed.
NCT05504837 reports 5 study locations spanning 4 distinct geographic areas - top geographies include New York, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT05504837 about?
NCT05504837 is a clinical study titled "A Study Assessing KB407 for the Treatment of Cystic Fibrosis". This study will evaluate safety and tolerability of ascending doses of nebulized KB407 in adults with cystic fibrosis.
What is the current status of trial NCT05504837?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2023-06-30. Estimated completion is 2026-01.
What conditions does trial NCT05504837 study?
This clinical trial studies the following conditions: Cystic Fibrosis.
What interventions are being tested in trial NCT05504837?
The interventions under investigation include: KB407 (Nebulization) (BIOLOGICAL).
Who is sponsoring clinical trial NCT05504837?
This trial is sponsored by Krystal Biotech, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05504837 being conducted?
This trial has 5 study locations across Florida, Illinois, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cystic Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease
RECRUITING · Phase 1
-
Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-581 in Healthy Participants
RECRUITING · Phase 1
-
A Phase 1/2 Trial of SP-101 for the Treatment of Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Evaluation of VX-828 in Healthy Participants and in Participants With Cystic Fibrosis
RECRUITING · Phase 1
-
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
RECRUITING · Phase 1
-
Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.